阿罗洛尔
阿罗洛尔 性质
| 熔点 | 148-149° |
|---|---|
| 沸点 | 599.8±60.0 °C(Predicted) |
| 密度 | 1.35 |
| 储存条件 | 2-8°C(protect from light) |
| 溶解度 | 可溶于DMSO（少许）、甲醇（少许） |
| 酸度系数(pKa) | 13.71±0.20(Predicted) |
| 形态 | 固体 |
| 颜色 | 灰白色至浅黄色 |
阿罗洛尔 用途与合成方法
|
5-HT 2A Receptor
|
Arotinolol shows its selectivity of β-adrenergic receptors, the result of Arotinolol for β1 and β2 adrenoceptors in 125 I-ICYP binding to rat cerebral cortical membranes with pK i value of 9.74 and 9.26 respectively. The selectively of β1 and β2 is equal. Arotinolol shows its potency for inhibiting the binding of the same radioligand to 5HT1B-serotonergic receptor site, Arotinolol displaces 125 I-ICYP binding to 5HT1B-receptors with the pK i values of 7.97 and 8.16 resepectively for β1 and β2 adrenergic receptors.
Arotinolol (oral gavage; 200 mg/kg; 8 weeks) can significantly decrease central arterial pressure (CAP) and pulse wave velocity (PWV), in addition, it reduces aortic collagen depositions and finally improves arterial stiffness in SHR mouse.
| Animal Model: | SHR mice |
| Dosage: | 200 mg/kg |
| Administration: | Orally gavage; 200 mg/kg; once daily; 8 weeks |
| Result: | Improved arterial stiffness in SHR. |
阿罗洛尔 化学药品说明书
阿罗洛尔 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-122537A | 阿罗洛尔 | 68377-92-4 | 5mg | 500 |
| 2026-09-15 | HY-122537A | 阿罗洛尔 | 68377-92-4 | 10mM * 1mLin DMSO | 550 |
